RXRX News & Events

Latest data shows the largest indicative borrow rate increases among liquid option names include: Merlin Inc (MRLN) 71.83% +3.66, Defiance 1.75x MSTR ETF (MSTX) 28.50% +1.20, Lucid Group (LCID) 26.37% +0.93, Equinor (EQNR) 2.11% +0.63, Recursion Pharmaceuticals (RXRX) 9.61% +0.59, Booking Holdings (BKNG) 0.82% +0.57, Beyond Meat (BYND) 25.72% +0.53, Spire Global (SPIR) 5.70% +0.42, Consumer Staples Sector SPDR ETF (XLP) 0.82% +0.38, and GraniteShares 1.5x Long COIN Daily ETF (CONL) 9.67% +0.27.

Latest data shows the largest indicative borrow rate increases among liquid option names include: Humacyte (HUMA) 19.23% +1.16, DeFi Development Corp (DFDV) 23.71% +0.78, Defiance Daily Target 2X Long HIMS ETF (HIMZ) 28.05% +0.67, ASP Isotopes Inc (ASPI) 1.97% +0.44, Vodafone (VOD) 9.09% +0.39, Recursion Pharmaceuticals (RXRX) 2.55% +0.35, DEFIANCE DAILY TARGET 2X LONG RIOT ETF (RIOX) 25.64% +0.32, Faraday Future Intelligent Electric Inc (FFAI) 11.15% +0.31, Vistra Energy (VST) 0.46% +0.21, and Bit Digital (BTBT) 0.66% +0.18.

Recursion Pharmaceuticals (RXRX) announced that Vicki Goodman will become Recursion's chief medical officer effective April 6 as David Mauro transitions out of the role. Previously, she was executive VP, product development and medical affairs and chief medical officer at Exelixis (EXEL).

PacBio (PACB) announced the appointment of Christopher Gibson, Ph.D., to PacBio's Board of Directors. Dr. Gibson is the co-founder and Chairman of the Board of Directors of Recursion (RXRX).